DrugPatentWatch Database Preview
Drugs in Development Information for LGX818
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug LGX818?
LGX818 is an investigational drug.
There have been 19 clinical trials for LGX818.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Rectal Neoplasms. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Memorial Sloan Kettering Cancer Center.
There are twenty-one US patents protecting this investigational drug and three hundred and twenty-one international patents.
Summary for LGX818
| US Patents | 21 |
| International Patents | 321 |
| US Patent Applications | 50 |
| WIPO Patent Applications | 26 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 34 |
Recent Clinical Trials for LGX818
| Title | Sponsor | Phase |
|---|---|---|
| Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer | Array BioPharma | Phase 1/Phase 2 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer | Bristol-Myers Squibb (BMS) | Phase 1/Phase 2 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer | University of California, San Francisco | Phase 1/Phase 2 |
Clinical Trial Summary for LGX818
Top disease conditions for LGX818
Top clinical trial sponsors for LGX818
US Patents for LGX818
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LGX818 | Start Trial | Compounds and compositions as protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | Start Trial |
| LGX818 | Start Trial | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | Array BioPharma Inc. (Boulder, CO) | Start Trial |
| LGX818 | Start Trial | Compounds and compositions as protein kinase inhibitors | IRM LLC (Hamilton, BM) Novartis AG (Basel, CH) | Start Trial |
| LGX818 | Start Trial | 3,4-diarylpyrazoles as protein kinase inhibitors | Nerviano Medical Sciences S.R.L. (Nerviano, IT) | Start Trial |
| LGX818 | Start Trial | 3,4-diarylpyrazoles as protein kinase inhibitors | Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LGX818
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LGX818 | Argentina | 077975 | 2029-08-28 | Start Trial |
| LGX818 | Australia | 2010286569 | 2029-08-28 | Start Trial |
| LGX818 | Canada | 2771775 | 2029-08-28 | Start Trial |
| LGX818 | China | 102725283 | 2029-08-28 | Start Trial |
| LGX818 | China | 103896921 | 2029-08-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
